Please login to the form below

Not currently logged in
Email:
Password:

Sutro

This page shows the latest Sutro news and features for those working in and with pharma, biotech and healthcare.

Celgene steps back from $1bn Sutro acquisition

Celgene steps back from $1bn Sutro acquisition

Celgene steps back from $1bn Sutro acquisition. Instead opts for amended licensing deal with US biotech. ... Celgene has decided not to acquire US biotech Sutro Biopharma, opting instead for an amended licensing deal with the cancer immunotherapy

Latest news

More from news
Approximately 4 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Pharma deals during October 2014 Pharma deals during October 2014

    Sutro receives an upfront of $95m with a further $90m in additional payments. ... Options also feature in the Celgene/Sutro deal and Roche/Heidelberg as noted above.

  • Deal Watch table for October 2014 Deal Watch table for October 2014

    1, 150. Sutro Biopharma/Celgene. Licence plus option to acquire Sutro. For development of multispecific antibodies and antibody drug conjugates (ADCs).

  • Deal Watch table for September 2014 Deal Watch table for September 2014

    300. Sutro / Merck KGaA. Licence and collaboration. Sutro's antibody drug conjugate technology for oncology.

  • Pharma deals during September 2014 Pharma deals during September 2014

    Boehringer Ingelheim has taken a licence to Curevac's messenger RNA vaccine for one of its compounds and the Californian company, Sutro, has signed an early stage deal with Merck KGaA

  • Pharma deals during December 2012 Pharma deals during December 2012

    A similar size deal that “ could be worth over $500m to Sutro” is the Celgene collaboration to design and develop novel antibody drug conjugates and bispecific antibodies for two undisclosed targets ... Sutro, based in California, is coy about the

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

  • V Bryan Lawlis joins board of KaloBios V Bryan Lawlis joins board of KaloBios

    Dr Lawlis is current president and CEO of Itero Biopharmaceuticals and is a director at several other life sciences companies including Biomarin Pharmaceutical, Geron, and Sutro Biopharmaceuticals.

  • Sutro Biopharma hires chief business officer and VP research Sutro Biopharma hires chief business officer and VP research

    Sutro Biopharma hires chief business officer and VP research. Dr Jeremy Bender and Dr Aaron Sato join as company prepares to advance antibody development. ... Dr Sato joins Sutro from OncoMed Pharmaceuticals, where he served as senior director of

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

Porterhouse Medical provides medical and scientific communication services to the pharmaceutical industry across the globe, with a focus on solutions...

Latest intelligence

No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...

Infographics